AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

662.355

-8.382-1.25%

Number of Gainers:12

Number of Losers:10

Number of Flat:21

PE:- -

High:674.135

Open:670.735

Low:661.038

Close:670.737

Volume:39.88M

Turnover:164.88M

Market Cap:93.26B

Float Cap:89.88B

Loading ...

NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus

Simply Wall St.

3 Founder Led Australian Stocks Built For Higher Rates

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?

Simply Wall St.

3 Penny Stocks With Real Revenue And Solid Balance Sheets

Simply Wall St.

Analysts Have Made A Financial Statement On Botanix Pharmaceuticals Limited's (ASX:BOT) Yearly Report

Simply Wall St.

Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen

Simply Wall St.

Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10

MT Newswires Live

Immuron FY26 Net Sales Rise 6% to AUD 7.7 Million

Immuron Reports FY26 Preliminary Results

THOMSON REUTERS

Paradigm Biopharmaceuticals - FY Net Loss Attributable A$56.3 Mln

THOMSON REUTERS

Immuron Posts FY Revenue from Ordinary Activities of A$7.71 Million

Imricor, Philips Collaborate on Interventional Magnetic Resonance Lab Product for Cardiac Intervention

MT Newswires Live

Immuron - Revenue from Ordinary Activities up 5.9% to A$7.71 Mln for Year Ended June 30, 2026

THOMSON REUTERS

Immuron - Loss from Ordinary Activities A$3.8 Mln for Year Ended June 30, 2026

THOMSON REUTERS

Imricor Medical Systems, Inc - Imricor and Philips Launch Commercial Imr Lab Solution

THOMSON REUTERS

Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?

Simply Wall St.

3 ASX Stocks Estimated To Be Trading At Discounts Up To 47% Below Intrinsic Value

Simply Wall St.

Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn

Simply Wall St.

Bell Potter Upgrades PolyNovo to Buy from Hold; Price Target is AU$1.22

MT Newswires Live

Actinogen Medical Ltd - FY Loss from Ordinary Activities After Tax Attributable A$15.4 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.etasphere.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":662.35516,"timestamp":1787896799803,"preClose":670.73676,"halted":0,"volume":39882195,"delay":0,"changeRate":-0.012496,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-8.381592,"latestTime":"08-28 16:00:00 AEST","open":670.7353,"high":674.135,"low":661.038,"amount":164882904,"amplitude":0.019526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787875200000,1787896800000]],"turnoverRate":0.001564,"increases":15,"decrements":12,"flats":16,"marketCap":93261150388.5,"floatMarketCap":89875216921.375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":674.135,"amplitude":0.019526,"preClose":670.73676,"low":661.038,"latestPrice":662.35516,"volume":39882195,"delay":0,"open":670.7353,"prevYearClose":644.3692,"prevWeekClose":662.355,"prevMonthClose":488.077,"prevQuarterClose":464.145,"fiveDayClose":653.313,"twentyDayClose":488.077,"sixtyDayClose":391.1,"secType":"PLATE","market":"AU","turnoverRate":0.001564,"marketCap":93261150388.5,"floatMarketCap":89875216921.375,"timestamp":1787896799803,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":10,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663445130","title":"NewMarket (NEU) Gains Momentum As Its Valuation Story Comes Back Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2663445130","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663445130?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:22","pubTimestamp":1788088921,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) is back on investor radars after recent share price moves and a fresh look at its valuation profile. The stock closed at US$914.69, with an estimated intrinsic discount of 32.5%.\nOver the past few months NewMarket’s share price has gained momentum, with a 30 day share price return of 7.6% and a 90 day share price return of 14.7%. The 5 year total shareholder return of 193.4% highlights how strongly long term holders have been rewarded.\nSpot similar momentum stories by scanning...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-gains-momentum-as-its-valuation-story-comes-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","DECU","VGFPF","BK7096","DCF","BK7508","PMDE","NEU.AU","RGLO","VOTE","GXDW","NEU","FEBU","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663721010","title":"3 Founder Led Australian Stocks Built For Higher Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2663721010","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663721010?lang=en_us&edition=fundamental","pubTime":"2026-08-30 01:17","pubTimestamp":1788023852,"startTime":"0","endTime":"0","summary":"Central banks are hinting that interest rates could stay higher for longer as inflation pressures persist. That kind of backdrop tends to reward leaders who think and act like long term owners. Founder led companies often fit that profile, with executives whose own wealth is tied to what you care about: long term equity value. This article highlights 3 founder led stocks from our screener that show how that mindset looks in practice.\nThe three founder led stocks in this article are just a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-maq/macquarie-technology-group-shares/news/3-founder-led-australian-stocks-built-for-higher-rates","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-maq/macquarie-technology-group-shares/news/3-founder-led-australian-stocks-built-for-higher-rates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7511","ZYAU.AU","IISV.AU","VAS.AU","EIGA.AU","OZR.AU","MQG.AU","STW.AU","E200.AU","BK7042","OZF.AU","XAO.AU","XJO.AU","BK7094","PME.AU","IMLC.AU","IOZ.AU","SLF.AU","XKO.AU","GEAR.AU","MAQ.AU","IIGF.AU","MSB.AU","BEAR.AU","DACE.AU","BK7046","QFN.AU","BBOZ.AU","GIVE.AU","QRE.AU","BK7501","BK7067","BK7043","BK7508","VAP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019945","title":"Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019945","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019945?lang=en_us&edition=fundamental","pubTime":"2026-08-29 06:23","pubTimestamp":1787955839,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers.\nFor long term holders, the key point is that this remains a highly...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663192110","title":"3 Penny Stocks With Real Revenue And Solid Balance Sheets","url":"https://stock-news.laohu8.com/highlight/detail?id=2663192110","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663192110?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:29","pubTimestamp":1787952565,"startTime":"0","endTime":"0","summary":"Global inflation readings in Europe are keeping interest rate expectations elevated, which keeps borrowing costs in focus for smaller companies. That is where the Financially Fit Penny Stocks screener becomes interesting. It filters for low priced stocks that still show solid financial health, so investors are not just chasing cheap tickers. This article highlights three stocks from the screener that may be worth considering for your watchlist.\nThe three stocks highlighted below are just a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/3-penny-stocks-with-real-revenue-and-solid-balance-sheets","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/3-penny-stocks-with-real-revenue-and-solid-balance-sheets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SIG.AU","BK7103","BK7508","BK4588","BK7067","BK7506","BK7501","ALK.AU","MSB.AU","BK4581","LABU","XLV","XBI","BK4585","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663601992","title":"Analysts Have Made A Financial Statement On Botanix Pharmaceuticals Limited's (ASX:BOT) Yearly Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2663601992","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663601992?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:17","pubTimestamp":1787951858,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/analysts-have-made-a-financial-statement-on-botanix-pharmace","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/analysts-have-made-a-financial-statement-on-botanix-pharmace","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7502","BK7508","BOT.AU","BOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701921","title":"Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701921","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663701921?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:28","pubTimestamp":1787948898,"startTime":"0","endTime":"0","summary":"Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway.\nConcerned by Actinogen Medical's cash runway...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-asxacw-shares-face-funding-pressure-as-los","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-asxacw-shares-face-funding-pressure-as-los","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064690","title":"Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064690","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662064690?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:43","pubTimestamp":1787913835,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has an average rating of overweight and mean price target of AU$19.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069805","title":"Immuron FY26 Net Sales Rise 6% to AUD 7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069805","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662069805?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:00","pubTimestamp":1787911229,"startTime":"0","endTime":"0","summary":"Immuron FY26 net sales rise 6% to AUD 7.7 millionImmuron posted record FY26 net sales of AUD 7.7 million, up 6% from the prior comparative period; second-half net sales rose 7%.FY26 net profit improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL52s1wJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585","IMC.AU","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","BK7067","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00BQXX3F31.USD","NDAQ","SG9999014005.SGD","LU0314104364.USD","BK7508","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD","LU2210150020.SGD","BK4588","BCDF","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069884","title":"Immuron Reports FY26 Preliminary Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662069884?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:00","pubTimestamp":1787911200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nTUA45KN3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662911058","title":"Paradigm Biopharmaceuticals - FY Net Loss Attributable A$56.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662911058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662911058?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:49","pubTimestamp":1787885347,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662031128","title":"Immuron Posts FY Revenue from Ordinary Activities of A$7.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662031128","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662031128?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:34","pubTimestamp":1787873652,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 MillionAug 28 -Immuron LtdIMC.AX:REVENUE FROM ORDINARY ACTIVITIES UP 5.9% TO A$7.71 MILLION FOR YEAR ENDED JUNE 30, 2026LOSS FROM ORDINARY ACTIVITIES A$3.8 MILLION FOR YEAR ENDED JUNE 30, 2026NO DIVIDENDS PAID OR DECLARED FOR YEAR ENDED JUNE 30, 2026Further company coverage:IMC.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662315210","title":"Imricor, Philips Collaborate on Interventional Magnetic Resonance Lab Product for Cardiac Intervention","url":"https://stock-news.laohu8.com/highlight/detail?id=2662315210","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662315210?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:18","pubTimestamp":1787872683,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems (ASX:IMR) collaborated with Royal Philips to offer an interventional magnetic resonance lab product for cardiac interventions, combining Philips' 1.5T magnetic resonance imagin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7503","BK7007","BK7508","IMR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662039949","title":"Immuron - Revenue from Ordinary Activities up 5.9% to A$7.71 Mln for Year Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662039949?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:38","pubTimestamp":1787870323,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662039946","title":"Immuron - Loss from Ordinary Activities A$3.8 Mln for Year Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662039946?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:38","pubTimestamp":1787870323,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003626","title":"Imricor Medical Systems, Inc - Imricor and Philips Launch Commercial Imr Lab Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662003626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:17","pubTimestamp":1787869025,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7503","IMR.AU","BK7007","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032654","title":"Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032654","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662032654?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:21","pubTimestamp":1787865674,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is in focus after releasing its full year 2026 results, issuing earnings guidance for 2027, and declaring a US$1.62 per share dividend. This combination gives investors several fresh data points to assess.\nThe CSL share price has reacted sharply around these results, with a 30 day share price return of 45.48% and a 90 day share price return of 79.98% taking it to A$173.88, even though the 1 year total shareholder return is still down 16.24% and the 5 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-results-2027-guidance-and-its-dividen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-results-2027-guidance-and-its-dividen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7511","BK7508","BK7501","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662396033","title":"3 ASX Stocks Estimated To Be Trading At Discounts Up To 47% Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2662396033","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662396033?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:04","pubTimestamp":1787857477,"startTime":"0","endTime":"0","summary":"As the Australian market navigates the implications of rising Consumer Price Index numbers and potential interest rate pressures, investors are keeping a close eye on undervalued opportunities amid these economic shifts. Identifying stocks that are trading below their intrinsic value can be a strategic move, especially in times when market conditions present both challenges and opportunities for discerning investors.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/3-asx-stocks-estimated-to-be-trading-at-discounts-up-to-47-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/3-asx-stocks-estimated-to-be-trading-at-discounts-up-to-47-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7005","BK7062","BK7051","BK7505","BK7104","BK7126","BK7095","BGL.AU","BK7015","NIC.AU","BK7084","DBB","BK7508","DUG.AU","NXL.AU","PNV.AU","BK7141","ING.AU","SLC.AU","NGI.AU","BK7162","SETM","ABV.AU","BK7016","ELS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662696084","title":"Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2662696084","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662696084?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:35","pubTimestamp":1787834131,"startTime":"0","endTime":"0","summary":"The market has Mesoblast trading around A$2.41 after a choppy week that left the stock down about 4% over seven days but still up double digits over one and three months. That price action suggests investors are torn between excitement over the story and concern about the cost of pursuing that growth.\nThe main takeaway from this earnings release is straightforward. Mesoblast reported its first full commercial year of RYONCIL revenue at US$115 million, yet still posted a net loss of US$57.5...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-shares-rally-meets-persistent-cash-burn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-shares-rally-meets-persistent-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7501","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662010706","title":"Bell Potter Upgrades PolyNovo to Buy from Hold; Price Target is AU$1.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2662010706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662010706?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:54","pubTimestamp":1787828045,"startTime":"0","endTime":"0","summary":"PolyNovo (ASX:PNV) has an average rating of overweight and mean price target of AU$1.28, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PNV.AU","BK7126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773768","title":"Actinogen Medical Ltd - FY Loss from Ordinary Activities After Tax Attributable A$15.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773768?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:29","pubTimestamp":1787812170,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":130,"code":"91000000","status":"200"}]}}